Doxorubicin News and Research

RSS

Doxorubicin hydrochloride is approved for use with other drugs as adjuvant therapy for breast cancer that has spread to the lymph nodes, including cancer that is HER-2 positive or has spread after surgery.

In addition to the uses that have been approved by the FDA, doxorubicin hydrochloride is sometimes used alone or with other drugs to treat other types of cancer. The drug continues to be studied in the treatment of many types of cancer.

New acoustofluidics method transforms intracellular nanoparticle delivery

A recent study published in Engineering presents an innovative acoustofluidics-based approach for intracellular nanoparticle delivery.

7 Mar 2025

Takumi-shaped DNA hydrogels show promise for targeted therapies

Hydrogels are polymeric materials with three-dimensional network structures containing large amounts of water. They serve as sustained-release drug delivery systems as they can encapsulate various bioactive substances, including drugs, antigens, and even cells.

13 Feb 2025

Green tea derived silver nanoparticles show promise against melanoma

Melanoma is a fast-progressing skin cancer characterized by a high mortality rate after metastasis. Local chemotherapy could be considered a therapeutic approach only in stage 0 of progression (in situ melanoma) and in the postoperative phase after surgical removal of suspected skin lesions.

3 Feb 2025

NUS researchers enhance chemotherapy with magnetic field pulses

Researchers at the National University of Singapore (NUS) have developed a non-invasive method to improve the effectiveness of chemotherapy while reducing its harmful side effects.

6 Jan 2025

TCR sequencing sheds light on tumor immune interactions in hepatocellular carcinoma

Hepatocellular carcinoma (HCC) stands as the dominant form of liver cancer, ranking as the fourth leading cause of cancer-related deaths globally.

11 Dec 2024

Serum protein panel test can help identify cardiomyopathy risk in childhood cancer survivors

Early disease detection is beneficial for securing the best possible outcomes for patients. But finding noninvasive, effective ways to predict disease risk is a tremendous challenge.

3 Dec 2024

Common heart failure drug reduces risk of chemotherapy-induced heart damage in cancer patients

A commonly prescribed medication for heart failure was linked to a lower risk of heart damage, or cardiotoxicity, among high-risk cancer patients undergoing chemotherapy treatment using anthracyclines, according to preliminary late-breaking science presented today at the American Heart Association's Scientific Sessions 2024.

18 Nov 2024

Tiny particles deliver combined heat and chemotherapy to tumors

Patients with late-stage cancer often have to endure multiple rounds of different types of treatment, which can cause unwanted side effects and may not always help.

29 Oct 2024

New drug WNTinib shows promise in treating pediatric liver cancer

A new drug called WNTinib can delay the growth of tumors and improve survival in hepatoblastoma, a type of liver cancer that occurs in young children.

22 Oct 2024

New insights into the mechanisms of efavirenz-induced neurotoxicity

Efavirenz is an important drug for treating HIV infection, but it has negative effects that can significantly impact patients' quality of life over time. It causes neuropsychiatric disorders and neurocognitive impairment in roughly 50 percent of patients. The drug is associated with abnormal lipid levels in blood plasma, but the molecular mechanisms responsible for negative clinical observations are unknown.

18 Sep 2024

2-bromopalmitate reduces senescence phenotype in human cells by modulating palmitoylation

A new research paper was published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science), Volume 16, Issue 16 on August 23, 2024, entitled, "2-Bromopalmitate treatment attenuates senescence phenotype in human adult cells - possible role of palmitoylation."

11 Sep 2024

SP-101 gene therapy shows promise for cystic fibrosis treatment

Scientists from Spirovant Sciences describe SP-101, a novel adeno-associated virus (AAV) gene therapy for the treatment of cystic fibrosis (CF) in the peer-reviewed journal Human Gene Therapy.

9 Sep 2024

New advances in Hodgkin's lymphoma treatment offer hope for affected individuals

Hodgkin's lymphoma (HL), impacting the lymph nodes and lymphatic system, has experienced a gradual increase in survival rates thanks to contemporary chemotherapy.

13 Aug 2024

Kaempferol's promise in fighting triple-negative breast cancer

Review highlights kaempferol's potential in treating triple-negative breast cancer through various anticancer mechanisms and improving chemotherapeutic efficacy.

24 Jul 2024

Tufts researchers uncover immune cell link to doxorubicin-induced heart damage

There's still much to learn about how doxorubicin, a 50-year-old chemotherapy drug, causes its most concerning side effects.

17 Jul 2024

Engineered E. coli optimizes targeted tumor cell killing and improves biosafety

Live bacteria can be applied in cancer therapy given their ability to deplete nutrients and induce cell death in tumors.

1 Jul 2024

UC San Diego engineers develop algae-based microrobots for lung cancer treatment

Engineers at the University of California San Diego have developed microscopic robots, known as microrobots, capable of swimming through the lungs to deliver cancer-fighting medication directly to metastatic tumors.

12 Jun 2024

Ultrasound technology breaks blood-brain barrier for glioblastoma treatment

In a major advance for the treatment of the deadly brain cancer glioblastoma, Northwestern Medicine scientists used ultrasound technology to penetrate the blood-brain barrier and provide a small dose of a chemotherapy and immunotherapy drug cocktail.

6 Jun 2024

Blocking CDK7 protein could prevent heart damage associated with cancer treatment

Blocking a protein known as CDK7 could prevent heart damage associated with a commonly used cancer chemotherapy medication, according to a study led by scientists at Washington State University.

4 Jun 2024

Study shows GHRH antagonist's role in AML drug resistance

A new research paper was published in Oncotarget's Volume 15 on April 8, 2024, entitled, "Exploring the role of GHRH antagonist MIA-602 in overcoming Doxorubicin-resistance in acute myeloid leukemia."

10 Apr 2024